104 related articles for article (PubMed ID: 15156275)
1. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity.
Su HB; Zhang YG; He JT; Mo W; Zhang YL; Tao XM; Song HY
Acta Biochim Biophys Sin (Shanghai); 2004 May; 36(5):336-42. PubMed ID: 15156275
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
3. [Expression, purification and characterization of a novel staphylokinase with anti-platelet aggregation activity].
Jingfang D; Jintian H; Ruiguang X; Xi C; Baohua Z
Wei Sheng Wu Xue Bao; 2008 Sep; 48(9):1186-91. PubMed ID: 19062642
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158.
Pulicherla KK; Kumar A; Gadupudi GS; Kotra SR; Rao KR
Biomed Res Int; 2013; 2013():297305. PubMed ID: 23998121
[TBL] [Abstract][Full Text] [Related]
5. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.
Collen D; Bernaerts R; Declerck P; De Cock F; Demarsin E; Jenné S; Laroche Y; Lijnen HR; Silence K; Verstreken M
Circulation; 1996 Jul; 94(2):197-206. PubMed ID: 8674179
[TBL] [Abstract][Full Text] [Related]
6. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
He J; Di J; Xu R; Zhao B
Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
[TBL] [Abstract][Full Text] [Related]
7. Modular design, expression and characterization of novel bifunctional mutants of fibrolase with combined platelet aggregation-inhibition and fibrinolytic activity.
Fang HM; Zhao L; Lu P; Chen SJ; Bao ZX; Qin YF; Zhu ZY; Zhao JM; Mai J; Zhang ST
Protein J; 2011 Apr; 30(4):247-52. PubMed ID: 21479991
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel Staphylokinase (SAK) mutant with low immunogenicity and its evaluation in rhesus monkey.
Wang M; Chen Y; Fu W; Zou M; Wang Y; Xing W; Wang J; Xu D
Int J Biol Macromol; 2020 Mar; 146():781-789. PubMed ID: 31730959
[TBL] [Abstract][Full Text] [Related]
9. Refolding of a staphylokinase variant y1-Sak by reverse dilution.
He J; Wang G; Xu R; Feng J; Wang J; Su H; Song H
Appl Biochem Biotechnol; 2008 Oct; 151(1):29-41. PubMed ID: 18785020
[TBL] [Abstract][Full Text] [Related]
10. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling.
Warmerdam PA; Plaisance S; Vanderlick K; Vandervoort P; Brepoels K; Collen D; De Maeyer M
Thromb Haemost; 2002 Apr; 87(4):666-73. PubMed ID: 12008950
[TBL] [Abstract][Full Text] [Related]
11. [Preparation and activity analysis of RGD-mSAK (K130T, K135R)].
Ning BA; Ma R; Zheng YL; Gao ZX; Shen B; Jiang YQ
Sheng Wu Gong Cheng Xue Bao; 2005 May; 21(3):456-60. PubMed ID: 16108374
[TBL] [Abstract][Full Text] [Related]
12. Comparison of expression optimization of new derivative of staphylokinase (SAK-2RGD-TTI) with the rSAK.
Faraji H; Ramezani M; Mashkani B; Sadeghnia HR; Benhangi HM; Hosseini Teshnizi S; Soltani F
Biotechnol Prog; 2019 Jul; 35(4):e2819. PubMed ID: 30972956
[TBL] [Abstract][Full Text] [Related]
13. Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation.
Swenson S; Bush LR; Markland FS
Arch Biochem Biophys; 2000 Dec; 384(2):227-37. PubMed ID: 11368309
[TBL] [Abstract][Full Text] [Related]
14. Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms.
Vakili B; Nezafat N; Negahdaripour M; Yari M; Zare B; Ghasemi Y
Curr Pharm Biotechnol; 2017; 18(13):1026-1037. PubMed ID: 29424308
[TBL] [Abstract][Full Text] [Related]
15. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.
Laroche Y; Heymans S; Capaert S; De Cock F; Demarsin E; Collen D
Blood; 2000 Aug; 96(4):1425-32. PubMed ID: 10942387
[TBL] [Abstract][Full Text] [Related]
16. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency.
Collen D; Stockx L; Lacroix H; Suy R; Vanderschueren S
Circulation; 1997 Jan; 95(2):463-72. PubMed ID: 9008465
[TBL] [Abstract][Full Text] [Related]
17. Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns.
Collen D; De Cock F; Demarsin E; Jenné S; Lasters I; Laroche Y; Warmerdam P; Jespers L
Circulation; 1997 Jan; 95(2):455-62. PubMed ID: 9008464
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous removal of T and B cell epitope in recombinant staphylokinase by structure-based mutagenesis of immuno-dominant Arg77 and Glu80 residues.
Xu R; He J; Jia K; Chen X; Liu J; Zhu K
Wei Sheng Wu Xue Bao; 2011 May; 51(5):692-703. PubMed ID: 21800633
[TBL] [Abstract][Full Text] [Related]
19. High yield production and purification of recombinant staphylokinase for thrombolytic therapy.
Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeid E; Pohl HD; Vanderschueren S; Van de Werf F; Michoel A; Collen D; Behnke D
Biotechnology (N Y); 1994 Feb; 12(2):185-9. PubMed ID: 7764434
[TBL] [Abstract][Full Text] [Related]
20. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities.
Chen H; Mo W; Zhang Y; Su H; Ma J; Yao R; Zhang S; Ge J; Song H
Eur J Pharmacol; 2007 Jul; 566(1-3):137-44. PubMed ID: 17451675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
